{"name":"Theresa Zesiewicz, MD","slug":"theresa-zesiewicz-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Gabapentin enacarbil extended release","genericName":"Gabapentin enacarbil extended release","slug":"gabapentin-enacarbil-extended-release","indication":"Other","status":"marketed"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Gabapentin immediate release","genericName":"Gabapentin immediate release","slug":"gabapentin-immediate-release","indication":"Postherpetic neuralgia","status":"marketed"}]}],"pipeline":[{"name":"Gabapentin enacarbil extended release","genericName":"Gabapentin enacarbil extended release","slug":"gabapentin-enacarbil-extended-release","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Gabapentin immediate release","genericName":"Gabapentin immediate release","slug":"gabapentin-immediate-release","phase":"marketed","mechanism":"Gabapentin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters.","indications":["Postherpetic neuralgia","Partial-onset seizures (adjunctive therapy)","Neuropathic pain"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxQYW15Q3VEbUZfUnZwWldDaXJXV2xRMk1Fb1lUSThLb3RkRzNqekdHUXl6YUw2SVF6SjZ4bFRzd0JLM1BJV2pfdE5UZlJua0FoSUtXZHVvV21Oc3o5SThNOEoyQ0VpbUp3M1cxMWVROW44VmFTd1ZUUmxDaWJtQXQ4NTA5LU9CREJoZlJwTWZMS2F0QWJTZEFfOWdOT1lEZG84NEw0cHVYV1ZzUG1uQmpRSUJidEJ5M21JVE1wbVUyTWZxUVV1WHpDU3dvaWlZeGs?oc=5","date":"2025-10-07","type":"trial","source":"neurologylive.com","summary":"Long-Term Data Suggest Friedreich Ataxia Agent Omaveloxolone Slows Disease Progression Over 4 Years - neurologylive.com","headline":"Long-Term Data Suggest Friedreich Ataxia Agent Omaveloxolone Slows Disease Progression Over 4 Years","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxOcWp0TnVsMFFDZXh4cWZkdGQ5Nk00eWRGb3Y5TjY3Y2dOME9hTGJjZjZZMnplMXVQTFdSai1PSDhLU3FZUURvdlVfTTU4NXdrd3ZpN24xbWthRTRkdzZxVUZCaW1oTFEwUlJVNjhZQ2VQU1RCWFJhUjc5NS15anhLRDV2aVZwMW1NNmlBbVZzX3NPR29JX3FVOFB0TFRQVm9vR3hsT3RYT0haZw?oc=5","date":"2023-08-22","type":"trial","source":"University of South Florida","summary":"USF Health $5.6 million study to define link between genetics and heart disease in many Friedreich’s ataxia patients - University of South Florida","headline":"USF Health $5.6 million study to define link between genetics and heart disease in many Friedreich’s ataxia patients","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}